76 related articles for article (PubMed ID: 38609317)
1. Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity.
Joy JD; Malacrida B; Laforets F; Kotantaki P; Maniati E; Manchanda R; Annibaldi A; Hopkins S; Garrobo-Calleja I; Gautrot J; Balkwill FR
Cancer Res; 2024 May; ():. PubMed ID: 38819641
[TBL] [Abstract][Full Text] [Related]
2. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.
Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J
Mol Ther; 2024 May; ():. PubMed ID: 38745414
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Profile of ROR1 Protein Expression across Tumor Types.
Raso MG; Barrientos Toro E; Evans K; Rizvi Y; Lazcano R; Akcakanat A; Sini P; Trapani F; Madlener EJ; Waldmeier L; Lazar A; Meric-Bernstam F
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791952
[TBL] [Abstract][Full Text] [Related]
4. Spatial CRISPR genomics identifies regulators of the tumor microenvironment.
Dhainaut M; Rose SA; Akturk G; Wroblewska A; Nielsen SR; Park ES; Buckup M; Roudko V; Pia L; Sweeney R; Le Berichel J; Wilk CM; Bektesevic A; Lee BH; Bhardwaj N; Rahman AH; Baccarini A; Gnjatic S; Pe'er D; Merad M; Brown BD
Cell; 2022 Mar; 185(7):1223-1239.e20. PubMed ID: 35290801
[TBL] [Abstract][Full Text] [Related]
5. Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.
Bandara V; Niktaras VM; Willett VJ; Chapman H; Lokman NA; Macpherson AM; Napoli S; Gundsambuu B; Foeng J; Sadlon TJ; Coombs J; McColl SR; Barry SC; Oehler MK; Ricciardelli C
Clin Transl Immunology; 2024; 13(5):e1512. PubMed ID: 38800555
[TBL] [Abstract][Full Text] [Related]
6. Anti-ROR1 CAR-T cells: Architecture and performance.
Osorio-Rodríguez DA; Camacho BA; Ramírez-Segura C
Front Med (Lausanne); 2023; 10():1121020. PubMed ID: 36873868
[TBL] [Abstract][Full Text] [Related]
7. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
8. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract][Full Text] [Related]
9. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
10. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.
Alabanza LM; Xiong Y; Vu B; Webster B; Wu D; Hu P; Zhu Z; Dropulic B; Dash P; Schneider D
Front Immunol; 2022; 13():832645. PubMed ID: 35222421
[TBL] [Abstract][Full Text] [Related]
11. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
[TBL] [Abstract][Full Text] [Related]
12.
Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
[TBL] [Abstract][Full Text] [Related]
13. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
[TBL] [Abstract][Full Text] [Related]
14. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Wang ML; Barrientos JC; Furman RR; Mei M; Barr PM; Choi MY; de Vos S; Kallam A; Patel K; Kipps TJ; Rule S; Flanders K; Jessen KA; Ren H; Riebling PC; Graham P; King L; Thurston AW; Sun M; Schmidt EM; Lannutti BJ; Johnson DM; Miller LL; Spurgeon SE
NEJM Evid; 2022 Jan; 1(1):EVIDoa2100001. PubMed ID: 38319241
[TBL] [Abstract][Full Text] [Related]
15. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
Xiao Z; Todd L; Huang L; Noguera-Ortega E; Lu Z; Huang L; Kopp M; Li Y; Pattada N; Zhong W; Guo W; Scholler J; Liousia M; Assenmacher CA; June CH; Albelda SM; Puré E
Nat Commun; 2023 Aug; 14(1):5110. PubMed ID: 37607999
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
